Understanding peptide safety profiles is essential for clinical decision-making. This reference covers adverse events, contraindications, drug interactions, and monitoring requirements for major peptide drug classes.

GLP-1 Receptor Agonists

Peptide	Common AEs	Serious AEs	Contraindications
Semaglutide	Nausea (20%), diarrhea, vomiting	Pancreatitis, thyroid C-cell tumors	Personal/family history of MTC, MEN2
Liraglutide	Nausea (40%), diarrhea	Pancreatitis, gallbladder disease	Same as semaglutide
Exenatide	Nausea (35%), injection site reactions	Pancreatitis	Same as semaglutide
Dulaglutide	Nausea (15%), diarrhea	Pancreatitis	Same as semaglutide

Insulin Analogs

Peptide	Common AEs	Serious AEs	Contraindications
All insulins	Hypoglycemia, weight gain, injection site reactions	Severe hypoglycemia, hypokalemia	Hypersensitivity to insulin

Growth Hormone Secretagogues

Peptide	Common AEs	Serious AEs	Contraindications
CJC-1295	Injection site reactions, flushing	Unknown long-term	Active malignancy
Ipamorelin	Headache, flushing	Unknown long-term	Same as CJC-1295
GHRP-6	Hunger, cortisol elevation	Unknown long-term	Same as CJC-1295

Safety Monitoring

1. Monitor glucose with all GH/GLP-1 peptides
2. Check thyroid function with GLP-1 RAs
3. Monitor liver function with GH secretagogues
4. Watch for injection site reactions with all injectable peptides
5. Report adverse events to FDA MedWatch

Immunogenicity Risk

Peptide Class	Immunogenicity Rate	Monitoring	Management
Insulin	5-30%	Anti-insulin antibodies	Switch formulation
GLP-1 RAs	<5%	Anti-drug antibodies	Discontinue if severe
GH analogs	10-30%	Anti-GH antibodies	Dose adjustment
Therapeutic peptides	Variable	Clinical response	Consider alternatives

Drug Interactions

Peptide	Interacting Drug	Effect	Management
Semaglutide	Oral contraceptives	Reduced efficacy	Use additional method
Insulin	Beta-blockers	Masked hypoglycemia	Monitor closely
GLP-1 RAs	Insulin	Additive hypoglycemia	Reduce insulin dose
Oxytocin	Prostaglandins	Enhanced uterine activity	Avoid combination

Emergency Protocols

Event	Immediate Action	Follow-up
Severe hypoglycemia	IV glucose, glucagon	Glucose monitoring
Anaphylaxis	Epinephrine, supportive care	Allergy evaluation
Pancreatitis	NPO, pain management	Discontinue GLP-1 RA
Thyroid nodules	Ultrasound, FNA	Discontinue GLP-1 RA

Safety equipment available from Kingston Peptides